本页面由Tiger Trade Technology Pte. Ltd.提供服务

Can-Fite Biopharma Ltd

4.34
+0.12002.84%
盘后4.13-0.2100-4.84%19:52 EST
成交量:4.56万
成交额:20.35万
市值:568.20万
市盈率:0.00
高:4.74
开:4.36
低:4.22
收:4.22
52周最高:46.60
52周最低:3.36
股本:130.92万
流通股本:123.88万
量比:0.34
换手率:3.68%
股息:- -
股息率:- -
每股收益(TTM):-2,665.2840
每股收益(LYR):-3,259.3317
净资产收益率:-264.12%
总资产收益率:-81.86%
市净率:1.36
市盈率(LYR):0.00

数据加载中...

2025/07/25

[修订]招股说明书

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2025/07/25

SEC问询函

Form CORRESP - Correspondence
2025/07/25

SEC问询函

Form CORRESP - Correspondence
2025/07/23

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2025/07/17

SEC问询函

Form CORRESP - Correspondence
2025/04/14

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/11/14

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/06

SEC问询函

Form CORRESP - Correspondence
2024/04/05

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/28

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/01/03

SEC问询函

Form CORRESP - Correspondence
2023/09/11

SEC问询函

Form CORRESP - Correspondence
2023/04/21

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/30

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/10

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2023/02/08

SEC问询函

CORRESP [Cover] - Correspondence
2023/01/31

招股说明书

F-1 - Registration statement for certain foreign private issuers
2022/03/24

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals